NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ANNX Stock Alerts $4.44 -0.10 (-2.20%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$4.44▼$4.6950-Day Range$4.44▼$7.8152-Week Range$1.57▼$8.40Volume840,796 shsAverage Volume1.50 million shsMarket Capitalization$399.73 millionP/E RatioN/ADividend YieldN/APrice Target$14.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Annexon alerts: Email Address Annexon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside225.0% Upside$14.43 Price TargetShort InterestHealthy3.99% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 5 Articles This WeekInsider TradingSelling Shares$49,514 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.36) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.32 out of 5 starsMedical Sector289th out of 909 stocksPharmaceutical Preparations Industry125th out of 425 stocks 4.5 Analyst's Opinion Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.99% of the outstanding shares of Annexon have been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Annexon has recently increased by 44.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANNX. Previous Next 1.8 News and Social Media Coverage News SentimentAnnexon has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Annexon this week, compared to 2 articles on an average week.Search InterestOnly 24 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have sold 154.91% more of their company's stock than they have bought. Specifically, they have bought $19,424.00 in company stock and sold $49,514.00 in company stock.Percentage Held by Insiders19.11% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Annexon are expected to grow in the coming year, from ($1.36) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Annexon Stock (NASDAQ:ANNX)Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More ANNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANNX Stock News HeadlinesApril 11, 2024 | insidertrades.comInsider Buying: Annexon, Inc. (NASDAQ:ANNX) Director Buys 3,200 Shares of StockApril 22, 2024 | americanbankingnews.comAnnexon, Inc. (NASDAQ:ANNX) Given Consensus Rating of "Buy" by AnalystsApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 20, 2024 | morningstar.comAnnexon Inc Ordinary SharesApril 17, 2024 | finance.yahoo.comAre Medical Stocks Lagging Annexon (ANNX) This Year?April 17, 2024 | finance.yahoo.comAre Medical Stocks Lagging Annexon (ANNX) This Year?April 16, 2024 | globenewswire.comAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | markets.businessinsider.comBuy Rating on Annexon Biosciences: Promising Pipeline and Strategic Growth PotentialApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 3, 2024 | globenewswire.comAnnexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM)March 28, 2024 | markets.businessinsider.comAnticipating Growth: Positive Outlook for Annexon Biosciences Amid Upcoming Clinical Trials and New Data ReadoutsMarch 27, 2024 | finanznachrichten.deAnnexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated MilestonesMarch 27, 2024 | markets.businessinsider.comAnnexon Biosciences (ANNX) Receives a Buy from TD CowenMarch 26, 2024 | globenewswire.comAnnexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated MilestonesMarch 18, 2024 | globenewswire.comAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)March 16, 2024 | ca.finance.yahoo.comANNX Jul 2024 7.500 putMarch 16, 2024 | ca.finance.yahoo.comANNX Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comANNX Apr 2024 7.500 putMarch 16, 2024 | finance.yahoo.comNational group to cut realtor commissions, make home-buying more affordableMarch 15, 2024 | finance.yahoo.comCannabis Grower Ascend Seeks Private Loan to Refinance DebtMarch 13, 2024 | seekingalpha.comHRTX, LUNA and ARQ among mid-day moversMarch 7, 2024 | finance.yahoo.comANNX Mar 2024 10.000 putMarch 2, 2024 | msn.comJP Morgan Upgrades Annexon (ANNX)February 27, 2024 | globenewswire.comAnnexon Biosciences to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comAnnexon Stock (NASDAQ:ANNX), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comAnnexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic ApproachSee More Headlines Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/23/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANNX CUSIPN/A CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees71Year FoundedN/APrice Target and Rating Average Stock Price Target$14.43 High Stock Price Target$30.00 Low Stock Price Target$7.00 Potential Upside/Downside+225.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.54% Return on Assets-53.52% Debt Debt-to-Equity RatioN/A Current Ratio14.72 Quick Ratio14.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book1.39Miscellaneous Outstanding Shares90,030,000Free Float72,822,000Market Cap$399.73 million OptionableOptionable Beta1.14 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Douglas Love Esq. (Age 56)J.D., CEO, President & Director Comp: $980.12kDr. Dean R. Artis Ph.D. (Age 62)Chief Scientific Officer & Executive VP Comp: $797.38kDr. Ted Yednock Ph.D. (Age 66)Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board Comp: $697.76kDr. Arnon Rosenthal Ph.D. (Age 68)Founder Ms. Jennifer Lew (Age 51)Executive VP, CFO & Corporate Secretary Comp: $624.2kMr. Michael Overdorf M.B.A. (Age 53)Executive VP & Chief Business Officer Comp: $580.47kHenk-Andre Kroon M.D.Senior Vice President of Translational MedicineDr. Jamie Dananberg M.D. (Age 66)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsNeurogeneNASDAQ:NGNECorbus PharmaceuticalsNASDAQ:CRBPEsperion TherapeuticsNASDAQ:ESPRBiomea FusionNASDAQ:BMEAOrganogenesisNASDAQ:ORGOView All CompetitorsInsiders & InstitutionsWilliam H CarsonBought 3,200 shares on 4/8/2024Total: $19,424.00 ($6.07/share)Virtu Financial LLCBought 48,614 shares on 2/26/2024Ownership: 0.091%BVF Inc. ILBought 7,000,000 shares on 2/15/2024Ownership: 13.148%Board of Trustees of The Leland Stanford Junior UniversitySold 11,619 shares on 2/15/2024Ownership: 0.906%Sectoral Asset Management Inc.Sold 247,874 shares on 2/14/2024Ownership: 1.223%View All Insider TransactionsView All Institutional Transactions ANNX Stock Analysis - Frequently Asked Questions Should I buy or sell Annexon stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANNX shares. View ANNX analyst ratings or view top-rated stocks. What is Annexon's stock price target for 2024? 6 equities research analysts have issued twelve-month target prices for Annexon's stock. Their ANNX share price targets range from $7.00 to $30.00. On average, they expect the company's stock price to reach $14.43 in the next twelve months. This suggests a possible upside of 225.0% from the stock's current price. View analysts price targets for ANNX or view top-rated stocks among Wall Street analysts. How have ANNX shares performed in 2024? Annexon's stock was trading at $4.54 at the beginning of 2024. Since then, ANNX stock has decreased by 2.2% and is now trading at $4.44. View the best growth stocks for 2024 here. Are investors shorting Annexon? Annexon saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,590,000 shares, an increase of 44.2% from the March 15th total of 2,490,000 shares. Based on an average trading volume of 1,570,000 shares, the days-to-cover ratio is presently 2.3 days. View Annexon's Short Interest. When is Annexon's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ANNX earnings forecast. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) announced its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.09. What ETFs hold Annexon's stock? ETFs with the largest weight of Annexon (NASDAQ:ANNX) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH).iShares Neuroscience and Healthcare ETF (IBRN). What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE). When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANNX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
